Physician profile
Mohan Phanse
NPI 1750343026
$476.98
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $101 · 2021: $34.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $168.73 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.51 | 2019-2020 | |
| Abbvie INC. | $52.13 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.82 | 2019 | |
| Ucb, INC. | $41.82 | 2019 | |
| Allergan, INC. | $20.85 | 2019 | |
| Concordia Pharmaceuticals INC. | $19.38 | 2019 | |
| Gilead Sciences, INC. | $18.58 | 2019 | |
| Pfizer INC. | $18.14 | 2020 | |
| Ironwood Pharmaceuticals, INC | $17.77 | 2019 | |
| Daiichi Sankyo INC. | $13.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Phanse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.